Amendments in the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

Claim 1. (currently amended): A compound of formula I,



I

~~in which~~ wherein

A is (C_1-C_8)alkyl, (C_0-C_8)alkylenearyl; a 3- to 12-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O_2 and S_2 and the 3- to 12-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, OCF_3, CN, (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C_1-C_6)alkyl, S-(C_1-C_6)alkyl, and NHCO(C_1-C_6)alkyl;

X is a bond, C(R8)(R9), C(OR10)(R11), O, N(R12), S, SO, SO_2, or CO;

R8, R9, R10, R11, R12 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

D is ~~N, or~~ C(R41);

E is ~~N, or~~ C(R42);

G is ~~N, or~~ C(R43);

L is ~~N, or~~ C(R44);

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, J, OH, CF_3, NO_2, CN, OCF_3, O-(C_1-C_6)alkyl, (C_1-C_4)alkoxyalkyl, S-(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_2-C_6)alkenyl, (C_3-C_8)cycloalkyl, O-(C_3-C_8)cycloalkyl, (C_3-C_8)cycloalkenyl, O-(C_3-C_8)-cycloalkenyl, (C_2-C_6)alkynyl, (C_0-C_8)alkylenearyl, -O-(C_0-C_8)alkylenearyl, S-aryl, N(R13)(R14), SO_2-CH_3, COOH, COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), CO(R21), or a 5- to 7-membered heterocycle having 1-4 heteroatoms;

R13, R14 are, independently of one another, H, (C_1-C_6)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C_1-C_6)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R17, R19 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

R18, R20, R21 are, independently of one another, (C_1-C_6)alkyl, or aryl;

B is N(R24)[[,]] or O;

R24 is H[[,]] or (C_1-C_6)alkyl;

R5 is H[[,]] or (C_1-C_6)alkyl;

W is ~~N, or~~ C(R25);

R25 is H, (C_1-C_6)alkyl, aryl, or a bond to Y;

T is ~~N, or~~ C(R26);

R26 is H, (C_1-C_6)alkyl, aryl, (C_0-C_8)alkylenearyl, or a bond to Y;

U is O[[,]] or S, ~~N(R27), C(R30)=N , or -N=C(R31);~~

~~R27, R30, R31 are independently of one another H, (C_1-C_6)alkyl, or a bond to Y;~~

Y is (C_1-C_8)alkylene, in which one or more carbons may be replaced by O, S, SO, SO_2, C(R32)(R33), CO, C(R34)$(OR35)_2$ or N(R36);

R32, R33, R34, R35, R36 are, independently of one another, H, (C_1-C_6)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 3- to 8-membered ring in which one or more carbons may be replaced by O, N, or S, and the 3- to 8-membered ring may carry further substituents such as (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, O-(C_1-C_6)alkyl, or NHCO(C_1-C_6)alkyl;

R37, R38, R39, R40 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

and the physiologically acceptable salts thereof.

Claim 2. (currently amended): **[[A]]** **The** compound of ~~**formula I as claimed in**~~ claim 1, wherein

A is (C_2-C_7)alkyl, (C_0-C_3)alkylenearyl; a 4- to 10-membered mono- or bicyclic ring which may contain one or more heteroatoms selected from the group consisting of N, O, and S, and the 4- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), O-(C_1-C_6)alkyl, and NHCO(C_1-C_6)alkyl;

X is a bond, C(R8)(R9), O, N(R12), S, or SO_2;

R8, R9, R12 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

D is ~~N, or~~ C(R41);

E is ~~N, or~~ C(R42);

G is ~~N, or~~ C(R43);

L is ~~N, or~~ C(R44);

~~where the total number of the nitrogen atoms defined by D, E, G and L is 0, 1 or 2~~;

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, Br, CF_3, NO_2, O-(C_1-C_6)alkyl, (C_1-C_6)alkyl, (C_3-C_8)cycloalkyl, O-(C_3-C_8)cycloalkyl, (C_2-C_6)alkynyl, (C_0-C_8)alkylenearyl, -O-(C_0-C_3)alkylenearyl, S-aryl, N(R13)(R14), SO_2-CH_3, COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), or CO(R21);

R13, R14 are, independently of one another, H, (C_1-C_6)alkyl, or R13 and R14, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R15, R16 are, independently of one another, H, (C_1-C_6)alkyl, or R15 and R16, together with the nitrogen atom to which they are bonded, form a 5- to 6-membered ring, wherein, in the case of the 6-membered ring, a CH_2 group may be replaced by O or S;

R17, R19 are, independently of one another, H, or (C_1-C_6)alkyl;

R18, R20, R21 are, independently of one another, (C_1-C_6)alkyl, or aryl;

B is N(R24)[[,]] or O;

R24 is H[[,]] or (C_1-C_6)alkyl;

R5 is H[[,]] or (C_1-C_6)alkyl;

W is ~~N, or~~ C(R25);

R25 is H, (C_1-C_6)alkyl, or aryl;

T is C(R26);

R26 is H, (C_1-C_6)alkyl, aryl, or a bond to Y;

U is O[[,]] or S, ~~N(R27), or N=C(R31)~~;

~~R27, R31 are, independently of one another, H, (C_1-C_6)alkyl, or a bond to Y~~;

Y is (C_1-C_4)alkylene, in which a carbon may be replaced by SO_2, C(R32)(R33), CO_2 or N(R36);

R32, R33, R36 are, independently of one another, H, (C_1-C_6)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 4- to 7-membered ring in which one or more carbons may be replaced by O, N, or S, and the 4- to 7-membered ring may carry further substituents selected from the group consisting of (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH, and $NHCO(C_1-C_6)$alkyl;

R37, R38, R39, R40 are, independently of one another, H, or (C_1-C_6)alkyl;

and the physiologically acceptable salts thereof.

Claim 3. (currently amended): **[[A]]** **The** compound of ~~**formula I as claimed in**~~ either of claims 1 and 2, wherein

A is (C_3-C_7)alkyl, (C_0-C_2)alkylenearyl; a 5- to 10-membered mono- or bicyclic ring which may contain 0, 1, or 2 heteroatoms selected from the group consisting of N, O, and S, and the 5- to 10-membered ring may carry further substituents selected from the group consisting of F, Cl, Br, NO_2, CF_3, (C_1-C_6)alkyl, aryl, O-(C_1-C_6)alkyl, and $NHCO(C_1-C_6)$alkyl;

X is a bond, C(R8)(R9), O, or N(R12);

R8, R9, R12 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

D is ~~N, or~~ C(R41);

E is ~~N, or~~ C(R42);

G is ~~N, or~~ C(R43);

L is ~~N, or~~ C(R44);

~~where the total number of the nitrogen atoms defined by D, E, G and L is 0 or 1~~;

R1, R2, R3, R41, R42, R43, R44 are, independently of one another, H, F, Cl, CF_3, NO_2, O-(C_1-C_6)alkyl, (C_1-C_6)alkyl, O-(C_3-C_8)cycloalkyl, (C_0-C_2)alkylenearyl, -O-(C_0-C_3)alkylenearyl, N(R13)(R14), COO-(C_1-C_6)alkyl, CON(R15)(R16), N(R17)CO(R18), N(R19)SO_2(R20), or CO(R21);

R13, R14 are, independently of one another, H[[,]] or (C_1-C_6)alkyl[[,]];

R15, R16 are, independently of one another, H[[,]] or (C_1-C_6)alkyl[[,]];

R17, R19 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

R18, R20, R21 are, independently of one another, (C_1-C_6)alkyl, or aryl;

B is N(R24);

R24 is H[[,]] or (C_1-C_6)alkyl;

R5 is H[[,]] or (C_1-C_6)alkyl;

W is ~~N, or~~ C(R25);

R25 is H, or (C_1-C_6)alkyl;

T is C(R26);

R26 is H, (C_1-C_6)alkyl, or a bond to Y;

U is O[[,]] or S~~, or N(R27)~~;

~~R27 is H, (C_1-C_6)alkyl, or a bond to Y;~~

Y is (C_1-C_3)alkylene, in which a carbon may be replaced by SO_2, C(R32)(R33) or CO;

R32, R33 are, independently of one another, H, (C_1-C_6)alkyl, or aryl;

R6, R7 are, independently of one another, H, (C_1-C_6)alkyl, (C_3-C_7)cycloalkyl, or R6 and Y or R6 and R7, together with the nitrogen atom to which they are bonded, form a 5- or 6-membered ring in which one or more carbons may be replaced by O or N, and the 5- or 6-

membered ring may carry further substituents selected from the group consisting of (C_1-C_6)alkyl, aryl, CON(R37)(R38), N(R39)(R40), OH and NHCO(C_1-C_6)alkyl;

R37, R38, R39, R40 are, independently of one another, H[[,]] or (C_1-C_6)alkyl;

and the physiologically acceptable salts thereof.

Claim 4. (currently amended): A pharmaceutical composition comprising one or more of the compounds ~~as claimed in~~ **of** claim 1 and a physiologically acceptable carrier.

Claim 5. (canceled)

Claim 6. (currently amended): A method for the prophylaxis or treatment of obesity, comprising administering to a mammal in need thereof an effective amount of **[[a]] the** compound ~~as claimed in~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claim 7. (currently amended): A method for the prophylaxis or treatment of type II diabetes, comprising administering to a mammal in need thereof an effective amount of **[[a]] the** compound ~~as claimed in~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claims 8-9. (canceled)

Claim 10. (currently amended): A method for preparing a pharmaceutical **composition,** comprising one or more of the compounds ~~as claimed~~ **of** claim 1, **[[which]]** compris**[[es]]ing** mixing the active substance with a pharmaceutically suitable carrier and bringing said mixture into a form suitable for administration.

Claim 11. (currently amended): A method for the prophylaxis or treatment of arteriosclerosis or high blood pressure, comprising administering to a mammal in need thereof an effective amount of **[[a]]** **the** compound ~~**as claimed in**~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claim 12. (currently amended): A method for normalizing lipid metabolism, comprising administering to a mammal in need thereof an effective amount of **[[a]]** **the** compound ~~**as claimed in**~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claim 13. (currently amended): A method for the prophylaxis or treatment of paresthesia, depression, anxiety, anxiety neuroses, or schizophrenia, comprising administering to a mammal in need thereof an effective amount of **[[a]]** **the** compound ~~**as claimed in**~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claim 14. (currently amended): A method for the prophylaxis or treatment of disorders associated with the circadian rhythm, comprising administering to a mammal in need thereof an effective amount of **[[a]]** **the** compound ~~**as claimed in**~~ **of** claim 1, or a physiologically acceptable salt thereof.

Claim 15. (currently amended): A method for the treatment of drug abuse, comprising administering to a mammal in need thereof an effective amount of **[[a]]** **the** compound ~~**as claimed in**~~ **of** claim 1, or a physiologically acceptable salt thereof.